Tag: coronavirus

Pfizer sets commercial price for Paxlovid at $1,390, doubling government cost

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

Pfizer on Wednesday (PFE.N) said it will set the U.S. price for its COVID-19 antiviral treatment Paxlovid at nearly $1,400 per five-day course when it moves to commercial sales after government stocks run out, more than double what the government currently pays for it.

The new list price, which does not include rebates and other discounts to insurers and pharmacy benefit managers, is $1,390 per course, Pfizer said in an emailed statement. The U.S. government paid around $530 per course for Paxlovid which has been made available to Americans at no cost.

Paxlovid, the most commonly prescribed at-home treatment for COVID-19 in the U.S., will remain available for free to patients there until the end of the year, Pfizer said.

Under an agreement with the government, the drug will also stay free of charge for patients insured under the Medicare and Medicaid programs through the end of 2024, and for uninsured and underinsured patients through 2028.

In Pfizer’s clinical trial, Paxlovid was shown to reduce hospitalizations and death by around 90% for unvaccinated people at risk for serious disease. In another trial, Pfizer was not able to show benefit for those considered at standard risk, including vaccinated patients.

Influential U.S. drug pricing watchdog the Institute for Clinical and Economic Review (ICER) said last year that its suggested price range for Paxlovid based on the benefits and value to patients was between $563 to $906 per course.

The United States purchased around 24 million courses of the oral two-drug treatment from Pfizer and still had a large supply, but arranged to return 7.9 million courses last week. The company also slashed its full-year revenue forecast due to lower-than-expected sales of its COVID-19 products.

Under that deal, a credit for the returned Paxlovid doses will pay for the supply to Medicare, Medicaid, underinsured and uninsured patients.

Demand for the drug has fallen since last year. In 2022, patients were given around 7 million courses of the drug, according to US government data. Through October 1, around 3.4 million courses had been administered in 2023.

The new list price was first reported by the Wall Street Journal.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Gatwick Airport caps flights: Are COVID-19 cases in the UK on a rise?

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

Concerns over COVID-19 infections are rising again in the United Kingdom after a slew of coronavirus-related flight cancellations left thousands grounded at Gatwick airport.

A recent outbreak among British air traffic control personnel, affecting about 30 percent of the staff, including COVID-19 cases, has forced London’s second-busiest airport, Gatwick, to implement a daily flight cap of 800 departures and arrivals until Sunday.

A spokesperson from the airport said, “Due to short notice sickness in the air-traffic control tower including cases of COVID-19, temporary air traffic control restrictions were put in place yesterday.”

The largest number of flight cancellations is expected on Friday, September 29.

According to the COVID-19 dashboard, the UK has reported a significantly higher number of cases in August  (1,445) and September (1,156) as compared to previous months.

Similarly, the rate of weekly positively of people receiving a PCR test for influenza has also been on the rise and has nearly doubled in September (0.84) as compared to June this year (0.4).

A rise in COVID-19 and flu cases is usually reported as countries in the West approach the winter months. In August, the new COVID variant EG.5.1 was the reason behind rising cases in the UK. One out of 10 COVID-19 cases in the UK were because of the new strain.

At Gatwick Airport, staff members are off sick due to various reasons, including COVID-19 and possibly the flu. The surge in cases comes during a transition in the UK Health Secretary Agency’s dashboard, which tracks and reports winter viruses.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

US FDA approves updated COVID-19 vaccines for enhanced protection

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

The US approved updated COVID-19 vaccines Monday, hoping to rev up protection against the latest coronavirus strains and blunt any surge this fall and winter.

The Food and Drug Administration decision opens the newest shots from Moderna and Pfizer and its partner BioNTech to most Americans even if they’ve never had a coronavirus vaccination. It’s part of a shift to treat fall updates of the COVID-19 vaccine much like getting a yearly flu shot.

There’s still another step: The Centers for Disease Control and Prevention must sign off. A CDC advisory panel is set to issue recommendations Tuesday on who most needs the updated shots. Vaccinations could begin later this week, and both the COVID-19 and flu shots can be given at the same visit.

A third vaccine maker, Novavax, said its updated shot is still being reviewed by the FDA.

COVID-19 hospitalizations have been rising since late summer although — thanks to lasting immunity from prior vaccinations and infections — not nearly as much as this time last year.

But protection wanes over time and the coronavirus continually churns out new variants that can dodge prior immunity. It’s been a year since the last time the vaccines were tweaked, and only about 20 percent of adults ever received that earlier update.

“Vaccination remains critical to public health and continued protection against serious consequences of COVID-19, including hospitalization and death,” FDA vaccine chief Dr. Peter Marks said in a statement. “We very much encourage those who are eligible to consider getting vaccinated.”

Just like earlier vaccinations, the fall round is cleared for adults and children as young as age six months. FDA said starting at age five, most people can get a single dose even if they’ve never had a prior COVID-19 shot. Younger children might need additional doses depending on their history of COVID-19 infections and vaccinations.

The FDA pointedly isn’t calling this latest round a “booster” but instead a vaccine updated to better match the currently circulating virus. The new recipe targets an omicron variant named XBB.1.5 — replacing outdated combination vaccines that mixed protection against the original coronavirus strain and an older version of omicron.

And while even the XBB.1.5 variant is no longer dominant, FDA determined that it’s close enough to coronavirus strains causing most COVID-19 illnesses today to offer good cross-protection. Like earlier versions, they’re expected to be most protective against COVID-19’s worst consequences rather than mild infection.

But while the FDA’s decision allows for wide use of the updated shots, the CDC will decide how strongly different groups are urged to get them.

Federal officials have said the shots still will be free to most Americans through private insurance or Medicare. But for the uninsured or underinsured, the CDC is working with health departments, clinics and certain pharmacies to temporarily provide free shots.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Indian study debunks heart attack risk linked to COVID-19 vaccines

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

There is no association between the COVID-19 vaccines used in India — Covishield and Covaxin — and an increase in the risk of heart attacks, according to an observational study that emphasises the protective effect of the jabs.

The research, published recently in the journal PLOS One, determined the impact of COVID-19 vaccination on mortality following acute myocardial infarction (AMI) or heart attack.

The retrospective study used data from 1,578 people admitted to GB Pant Hospital in Delhi between August 2021 and August 2022. As many as 1,086 (68.8 percent) were vaccinated against COVID-19 while 492 (31.2 percent) were unvaccinated.

Among the vaccinated group, 1,047 (96 percent) had received two doses of the vaccine while 39 (4 percent) had received only a single dose.

“Our study found that vaccines used in India are safe. There was no association of vaccination in India with heart attack. In fact, the study found that there were less chances of death after heart attack in vaccinated individuals,” Mohit Gupta, who led the study, from GB Pant Hospital, told PTI.

The adverse effects (AEs) of COVID-19 vaccines have mostly been mild, transient and self-limiting. However, concerns have been raised regarding the cardiovascular adverse effects of these vaccines.

Any side effect can have catastrophic effects, especially in large densely populated countries such as India, the authors noted.

In all the enrolled patients, data regarding the patient’s vaccination status including details on the type of vaccine, date of vaccination and adverse effects were obtained.

The researchers found that the analysis did not show a specific clustering of AMI at any particular time post-vaccination, suggesting there was no significant association between COVID-19 jabs and heart attacks.

On 30-day follow-up, all-cause mortality occurred in 201 (12.7 percent) patients with adjusted odds of mortality being significantly lower in the vaccinated group.

Similarly, at six months of follow-up, the vaccinated AMI group had lower odds of mortality as compared to the non-vaccinated group.

COVID-19 vaccines showed a decrease in all-cause mortality at 30 days and six months following AMI, according to the study.

However, increasing age, diabetics and smokers had a higher risk of 30-day mortality, the researchers said.

“Findings of our study showed that the 30-day and six-month all-cause mortality risk was significantly lower in the vaccinated subjects as compared to the unvaccinated population,” the authors of the study said.

This study is the first to be conducted among a larger population of AMI patients which has shown the COVID-19 vaccine to be not only safe but also have a protective effect in terms of reduction of all-cause mortality both on short term as well as at six months of follow-up, the authors of the study said.

They noted some limitations, saying that this was a single-centre retrospective study, and the findings need to be validated in further larger studies from different ethnic groups.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

ICMR study: Who’s more at risk after leaving the hospital with COVID-19?

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

The Indian Council of Medical Research (ICMR) recently published a research paper highlighting varying vulnerability to post-discharge mortality in COVID-19 cases. The study highlights three risk factors for death after discharge while also highlighting the importance of vaccinating prior to contracting the coronavirus.

“Post-discharge mortality” refers to the occurrence of death after a person has been discharged from a medical facility, such as a hospital, following treatment for a specific medical condition.

The new ICMR study, titled “Determinants of post-discharge mortality among hospitalized COVID-19 patients,” identifies three prominent risk factors associated with post-discharge mortality among COVID-19 survivors. People over the age of 40, men with co-morbidities and individuals who endured moderate to severe COVID-19 cases have a more pronounced risk of post-charge mortality.

On a more positive note, the study reveals that those who received at least one dose of the SARS-CoV-2 vaccine before contracting the virus experienced a 60 percent reduction in the risk of post-discharge mortality.

The research accumulated results from 14,419 participants hailing from 31 hospitals nationwide, who were followed up for a period ranging from four weeks to one-year post-discharge. 942 individuals (6.5 percent) had succumbed, while the remaining 93.5 percent were documented as alive during the year-long follow-up.

“Similar trends were seen in participants, 18-45 years of age,” the ICMR team said.

While the findings offer valuable insights, the study acknowledges limitations stemming from telephonic follow-ups, which could lead to symptom underreporting. Also, the study’s focus was exclusively on hospitalised COVID-19 patients, which restricts the generalisability of the conclusions to the broader population.

In parallel to this study, the ICMR is currently overseeing a multicentric hospital-based matched case-control study, which seeks to investigate the impact of the COVID-19 vaccine on heart attacks among individuals aged 18–45 years in India.

Furthermore, the ICMR is actively researching factors associated with sudden deaths among adults aged 18–45 years in India.

Meanwhile, PK Mishra, the principal secretary to Prime Minister Narendra Modi, on Monday, held a high-level meeting to review the global and national COVID-19 situation in view of the new variants, Pirola (BA.2.86) and Eris (EG.5).

During the meeting, Mishra highlighted the need for states to monitor trends of influenza-like illnesses despite the stable COVID-19 situation, and prepared healthcare systems. He also focused on the need to send enough samples for genome sequencing.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

‘Eris’ or EG.5.1.1: Maharashtra records single case of new COVID-19 Omicron subvariant

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

Maharashtra has recorded its first and only case of the new coronavirus Omicron subvariant named EG.5.1.1 or “Eris.” Officials, however, have not released any information on the individual who contracted the variant or any details on gender, age and travel history.

However, there is no cause for alarm, officials said on Wednesday, as there is only one recorded case from May.

“The variant, EG.5.1.1, was found in May and we have been monitoring it. It is not of any public health importance,” Babita Kamlapurkar, the health surveillance officer for Maharashtra, said.

Is there cause for concern?

The Eris variant is said to be the most dominant in the United States and makes up the largest proportion of new COVID-19 infections, according to the Centers for Disease Control and Prevention.

However, officials believe it’s not as bad as previous subvariants which caused large spikes in cases. COVID-19 hospitalisations are on the rise in the US which reported a 12 percent hike in hospital admissions in a week, coming to about  9,056 as of July 29.

“There are a couple that we’re watching, but we’re not seeing anything like delta or omicron,” Cristin Young, an epidemiologist at Biobot Analytics, the CDC’s wastewater surveillance contractor, said, referencing variants that fueled previous surges.

And mutations in the virus don’t necessarily make it more dangerous.

“Just because we have a new subvariant doesn’t mean that we are destined to have an increase in bad outcomes,” Dowdy said.

How can we be prepared?

In the US, updated coronavirus vaccines that contain one version of the omicron strain called XBB.1.5, are likely to be rolled out before the end of the year. It’s an important change from today’s combination shots, which mix the original coronavirus strain with last year’s most common omicron variants.

However, itt’s not clear exactly when people can start rolling up their sleeves for what officials hope is an annual fall COVID-19 shot.

Maharashtra’s Babita Kamlapurkar also emphasised the importance of maintaining COVID-19-appropriate behaviour, particularly during the months of June, July and August, which historically witness an upswing in case numbers.

“There is no reason to worry. The Centre has also said it has been continuously monitoring the variant and there is no need to worry,” she confirmed.

Kamlapurkar reiterated that regular surveillance of COVID-19 variants remains an ongoing practice.

With agency inputs.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Wuhan researcher claims China engineered COVID-19 as a ‘bioweapon’

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

COVID 19: New research sheds light on cause behind long COVID — All you need to know

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

New research in immunology this week has shed light on a possible cause of long COVID. Researchers from the Allen Institute and Fred Hutchinson Cancer Center have discovered that an overactive inflammatory response could be at the root of many long COVID cases.

Broadly defined as “signs, symptoms and conditions that continue or develop after initial COVID-19 infection” by the US Centres for Disease Control and Prevention (CDC), the concept of long COVID has long eluded people.

Most patients report experiencing prolonged symptoms even after recovering from COVID-19 although there is no test to diagnose long COVID.

This new study, published in the journal Nature Communications on June 9, examined proteins present in the blood of patients and identified a set of molecules associated with inflammation that were only found in a subset of long COVID patients, but not in those who had fully recovered.

ALSO READ | People with long COVID smell loss have reduced brain activity, study finds

The study analysed blood samples from 55 patients with long COVID, finding that around two-thirds of them had consistently high levels of inflammation signals.

In comparison, blood samples from 25 individuals who had recovered from COVID-19 and 25 volunteers who had never been infected did not exhibit the same signs of inflammation.

While previous studies have hinted at a connection between inflammation and long COVID, this study is the first to trace the persistence of inflammatory markers over time in the same patients.

The findings have significant implications for potential treatments. Dr Troy Torgerson, Director of Experimental Immunology at the Allen Institute for Immunology, suggests that certain anti-inflammatory drugs could alleviate symptoms for some long COVID patients.

However, it is crucial to determine which patients would benefit from specific treatments. This calls for precision medicine approaches to address the enigmatic nature of long COVID.

“The big question was, can we define which long COVID patients have persistent inflammation versus those that don’t? That would be useful in terms of clinical trial planning and in terms of helping clinicians figure out targeted treatments for their patients,” Torgerson said.

ALSO READ | What is Long COVID? Here’s the latest on its causes, symptoms and more

The study identified distinct blood markers in the subset of patients with “inflammatory long COVID,” which resemble inflammation patterns observed in autoimmune diseases like rheumatoid arthritis.

JAK inhibitors, a class of drugs used to treat rheumatoid arthritis, may hold promise for addressing this type of inflammation. However, their effectiveness for long COVID has not yet been tested.

The researchers aim to further refine their understanding of “inflammatory long COVID” by identifying a few specific markers that can be used in clinical settings to distinguish this subset of patients.

ALSO READ | High cholesterol and weight, reduced physical stamina may signal long COVID: Lancet study

This research is part of the larger Seattle COVID Cohort Study, led by Dr. Julie McElrath and Julie Czartoski at the Fred Hutchinson Cancer Center.

The Seattle COVID Cohort Study was launched in 2020 to observe immune responses in patients with mild to moderate COVID-19. Initially, the study aimed to investigate successful immune responses that led to full recovery. However, the researchers soon realised that some individuals, even among those with mild cases, experienced persistent symptoms.

These findings prompted the expansion of the study to include more long COVID patients, analysing a panel of 1500 proteins in their blood. By understanding the molecular roots and subsets of the disease, researchers hope to guide the design of clinical trials and treatment decisions tailored to each group.

ALSO READ | Pfizer aims to roll out COVID-19 vaccines targeting XBB.1.5 strain by July

“The ultimate goal is to treat patients,” Talla said. “Although we call everything long COVID, what’s come out of this work shows us that we might not be able to give everyone the same kinds of therapies and we shouldn’t put everyone into one group for treatment purposes.”

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

COVID-19 | India reports decline in active cases, Mexico develops vaccine after 2 years

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

India has reported a decrease in the number of active coronavirus cases, which currently stands at 36,244, down from 40,177. The health ministry’s latest data, updated on Thursday, shows that the country recorded 3,962 new infections in the past 24 hours.

The national daily positivity rate now stands at 2.17 percent.

Despite the decrease in active cases, the death toll has increased to 5,31,606, with 22 deaths reported, including seven reconciled by Kerala, as per the ministry’s update at 8 am. The total COVID-19 case tally in India is 44.9 million.

ALSO READ | Pfizer’s Q1 results beat estimates despite sharp COVID-19 vaccine sales drop

The active cases currently comprise only 0.08 percent of the total infections, and the national COVID-19 recovery rate has been recorded at an impressive 98.73 percent, the ministry said.

Furthermore, 4,43,92,828 people have recovered from the disease so far, and the case fatality rate stands at 1.18 percent.

Delhi reported 272 new COVID-19 cases with a positivity rate of 8.39 percent and one death, the local health department recorded on Thursday.

ALSO READ | World needs better COVID vaccines, says CEPI CEO

The ministry’s website also reports that 2.2 billion doses of the coronavirus vaccine have been administered across the country under the nationwide vaccination drive.

According to the Press Information Bureau, 2,363 doses of the vaccine were administered in the past 24 hours.

Mexico develops own COVID-19 vaccine called Patria

Mexico has finally developed its own COVID-19 vaccine, called Patria or Motherland, more than two years after inoculations from the US, Europe and China were rolled out, AP reported.

The vaccine is a joint effort between the government and a Mexican company, Avimex, which previously worked on animal vaccines.

Vaccine uptake in Mexico dropped in late 2022 and 2023, and Mexico still has millions of doses of the Abdala vaccine it bought from Cuba.

ALSO READ | India completes 2 years of COVID vaccination — the success story so far

Patria will be used as a booster shot, though Dr Fidel Alejandro Sánchez, a council member of Mexican researchers, has doubts about using the vaccine, which was designed two years ago, against currently circulating virus strains.

“It is like reading yesterday’s newspaper,” Sánchez said. “It makes no sense to use it as a booster when it wasn’t designed for that.”

It is unclear whether the government medical approval agency has formally authorized Patria.

Mexico’s official death toll of test-confirmed COVID-19 deaths stands at almost 334,000, but testing was scarce in the early days of the pandemic and the government’s own review of death certificates shows more than 505,000 deaths where COVID-19 was listed as a cause of contributing cause of death.

With agency inputs.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

India COVID-19 update | Mizoram reports first death in 6 months

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

India has recorded 3,720 new COVID-19 infections, bringing the total number of cases to 44.9 million, according to the latest data from the Union Health Ministry. The count of active cases of the disease in the country stands at 40,177.

The data, which was updated on Wednesday at 8 am, also revealed that the death toll due to the viral disease has increased to 5,31,584 with 20 new fatalities, including five reconciled by Kerala.

The national COVID-19 recovery rate has been recorded at 98.73 percent, while active cases now comprise 0.09 percent of the total infections. The number of people who have recuperated from the disease has surged to 4,43,84,955 while the case fatality rate was recorded at 1.18 percent.

ALSO READ | US ends COVID-19 vaccine requirement for international travellers effective May 11

Delhi on Tuesday reported 289 fresh COVID-19 cases with a positivity rate of 9.74 percent. It added one more COVID-related fatality, bringing the total case count to 20,39,270 and the death toll to 26,633.

The Union Health Ministry’s website shows that India has administered over 2.2 billion doses of the coronavirus vaccine under the nationwide COVID-19 vaccination drive. According to the Press Information Bureau, 2,459 doses of the vaccine were administered in the last 24 hours.

ALSO READ | Idli-sambar and rajma-rice may have helped Indians in their fight against Covid-19, says study

India has been battling the COVID-19 pandemic since March 2020, and despite several waves, has been able to keep the spread of the virus under control. The country has been ramping up its vaccination booster drive to protect its citizens against the virus.

Mizoram reports first death in over 6 months

Mizoram reported its first COVID-19 death in over six months after an elderly man died due to the virus in Aizawl. The 63-year-old man was admitted to a private hospital in the city and passed away on Monday. The last coronavirus-related death in Mizoram was reported on October 29, 2022.

ALSO READ | 20 MW Vankal Solar Park inaugurated in Mizoram, first in northeast India

The state’s health department announced that 34 new COVID-19 cases were reported in the last 24 hours, raising the number of active cases to 78. The total number of coronavirus infections in Mizoram has reached 2,39,086, with 727 fatalities and 2,38,281 recoveries.

With agency inputs.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow